uniQure (QURE) updated FIX activity and durability from AMT-060 and its AMT-061 programs at ASH, with the former approaching four years and the latter at the one-year time point, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. The analyst believes AMT-061 has a "best in class" profile for subjects with hemophilia B over Spark Therapeutics' (ONCE) SPK-9001. uniQure's ongoing HOPE-B registration study with a topline readout during Q4 of 2020 should position AMT-061 as the "first one-and-done" gene therapy for hemophilia B, contends Chattopadhyay, who has a Buy rating on the shares with a $73 price target.